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CHALLENGES IN THE USE OF SCALE-DOWN MODELS FOR UNDERSTANDING AND MITIGATING 
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Scale-down models are commonly used to execute process characterization studies, as well as to screen raw 
materials and to conduct investigations in support of manufacturing operations.  During the clinical manufacture 
of a monoclonal antibody, consistent product quality was maintained; however, large variations in bioreactor 
harvest titer (> 2X) were observed between lots.  Root cause analysis of this variation did not establish a linkage 
between culture performance and manufacturing execution or deviations.  Further, small scale satellite reactor 
performance displayed lesser variability; thereby eliminating seed train and raw materials as potential root 
causes.  Small scale investigations, using multiple scale-down models, were not able to reproduce the variability 
in product titer, and other cell culture metrics, observed at large scale.  However, these studies were able to 
establish a correlation between cellular metabolism, feeding strategy and harvest titer.  As a result, process 
modifications have successfully been developed to obtain a more robust production bioreactor process while 
maintaining product quality. 
 
